Health Canada approves DUPIXENT® (dupilumab injection)

Fifth indication for DUPIXENT
® in Canada following approvals for moderate-to-severe atopic dermatitis in adults and adolescents, severe chronic rhinosinusitis with nasal polyposis, and severe asthma in adults and adolescents.
For those living with atopic dermatitis, itch has the highest impact on a patient's quality of life.
1
Results from a survey conducted among Canadian children with atopic dermatitis found that 70 per cent experienced loss of sleep and 30 per cent experienced anxiety due to their condition.
2
MISSISSAUGA, ON, Feb. 23, 2021 /CNW/ - Sanofi Canada announced today that Health Canada has approved DUPIXENT
® (dupilumab injection) for the treatment of moderate-to-severe atopic dermatitis (AD) in children aged six to 11 years whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.

Related Keywords

Canada , Canadians , Canadian , Melinda Gooderham , Marissa Poole , Skin Centre For Dermatology , Youtube , Eczema Society Of Canada , Health Canada , Medical Director , Eczema Society , Country Lead , Sanofi Canada , General Manager , Sanofi Genzyme , கனடா , கனடியர்கள் , கனடியன் , மெலிண்டா குட்ஹாம் , மரிசா பூல் , தோல் மையம் க்கு தோல் நோய் , வலைஒளி , அரிக்கும் தோலழற்சி சமூகம் ஆஃப் கனடா , ஆரோக்கியம் கனடா , மருத்துவ இயக்குனர் , அரிக்கும் தோலழற்சி சமூகம் , நாடு வழி நடத்து , சனோஃபி கனடா , ஜநரல் மேலாளர் ,